Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis - PubMed

4 hours ago

Tirzepatide is a dual agonist of GIP and GLP-1 receptors, showing efficacy in glycemic control and weight loss for T2DM.
As adjunct therapy in overweight or obese adults with T1DM, it significantly improves HbA1c, reduces body weight and BMI, and lowers insulin requirements.
Meta-analysis of 6 observational studies found HbA1c decreased by 0.61%, weight by 9.9 kg, BMI by 8.3 kg/m2, and total daily insulin by 23.73 IU at 6 months.
Common adverse effects were gastrointestinal symptoms like nausea, vomiting, and loss of appetite.
Evidence is limited by observational designs and overlapping cohorts; larger randomized controlled trials are needed for confirmation and long-term safety assessment.

Hasty Briefsbeta